Other analysts also recently issued reports about the stock. Oppenheimer downgraded shares of Global Blood Therapeutics to a market perform rating in a research report on Monday, August 15th. Wells Fargo & Company downgraded Global Blood Therapeutics from an overweight rating to an equal weight rating and upped their target price for the stock from $66.00 to $68.50 in a research report on Tuesday, August 9th. Cowen cut Global Blood Therapeutics to a market perform rating and lifted their price target for the company from $67.00 to $68.50 in a research report on Tuesday, August 9th. Canaccord Genuity Group raised Global Blood Therapeutics from a hold rating to a buy rating and boosted their price objective for the stock from $40.00 to $72.00 in a research note on Monday, August 8th. Finally, Wedbush cut Global Blood Therapeutics to a neutral rating in a research note on Monday, August 15th. Twelve investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Global Blood Therapeutics presently has an average rating of Hold and a consensus price target of $65.42.
Global Blood Therapeutics Price Performance
Shares of GBT opened at $68.49 on Monday. Global Blood Therapeutics has a one year low of $21.65 and a one year high of $73.02. The stock’s fifty day moving average is $68.37 and its 200-day moving average is $50.85. The company has a debt-to-equity ratio of 4.92, a quick ratio of 6.17 and a current ratio of 6.88. The firm has a market capitalization of $4.62 billion, a price-to-earnings ratio of -13.67 and a beta of 0.45.
Hedge Funds Weigh In On Global Blood Therapeutics
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.